搜索到 1000 条关于 Ʊ׶ ʸ ı vbk796.top Ʊ׶ ̸? ı ߱ġŹ ϴ° ͳ ౹ Ʊ׶ 的文章

2012.09.19 2010 第五届国际基因组学大会(ICG-V)

, please click: http://www.genomeconference.org/pages/Abstract.aspxTop Poster

2012.09.19 2012 中国医疗器械高峰论坛

trials and regulatory affairs
A special showcase of top 10 Chinese innovative device companies and top 5 selected US/EU device companies interested in China
CT 引导下对小于 8 mm 的肺结节活检诊断可行性及安全性评估

2019.03.18 CT 引导下对小于 8 mm 的肺结节活检诊断可行性及安全性评估

Radiol.2018 Feb;28(2):796-806.
中国非小细胞肺癌患者 AZD9291 耐药机制

2018.05.29 中国非小细胞肺癌患者 AZD9291 耐药机制

突变的时间的中位数为 PD 前 2.8(1.4-8.4)个月。在 13 例患者中发现了 EGFR 扩增、L718Q、I744T、C775Y、G796
《凉凉》

2018.04.11 《凉凉》

、渭南市妇幼保健医联体牵头单位,渭南市医学会儿科、新生儿科、儿保科、超声科、妇科肿瘤学术委员会主委单位。医院占地35.86亩,开放病床550张,现有职工796
浙江:2017 省自然科学基金重点和杰青项目验收会通知

2017.02.15 浙江:2017 省自然科学基金重点和杰青项目验收会通知

各依托单位、有关项目负责人:现将 2017 年度浙江省自然科学基金重点和杰青项目验收会有关事项通知如下:一、会议时间:2017 年 3 月 14-17 日二、会议地点:浙江紫金港国际饭店(杭州市西湖区申花路 796 号)三、验收要求:1. 项目负责人应提供经所在单位审核的验收材料及其附件,附件包括:《资助项目研究计划
老年T2DM患者痴呆风险存在种族差异

2013.12.31 老年T2DM患者痴呆风险存在种族差异

风险模型拟合分析。结果显示,3,796名患者(17.1%)被诊断为痴呆。土著美国人和非裔美国人经年龄校正的痴呆发病密度最高,分别为34
低基线CD4+水平为ART治疗后骨质流失的独立危险因素

2013.08.19 低基线CD4+水平为ART治疗后骨质流失的独立危险因素

(BMI)、丙型肝炎状态、parent研究、HIV-1 RNA水平等。研究结果发现,在纳入研究的796名受试者中,第96周全身骨密度降低2.0

2020.06.17 【直播 | 现场】计算机辅助设计—分子模拟与蛋白互作研讨班(8.20-22)

。【报名回执】访问此链接填写报名回执(https://www.wjx.top/jq/80710449.aspx)【咨询请联系】QQ 号:2814500767邮箱

2012.09.19 2011年生物仿制药会议(Biosimilars Asia 2011)

时间: 2011-5-23 至 2011-5-26
地点:Grand Hyatt Shanghai
主办单位: IBC Asia (S) Pte Ltd

会议简介

According to Business Insights, an estimated $25bn worth of biologics will lose patent protection by 2016, creating a significant market opportunity for biosimilars. However, the reality is that biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know-how, clinical-trial capabilities, and a high level of financial investment.

Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry. It is estimated that it costs between US$100-200 million to bring a biosimilar product to market. With so much at stake, biosimilars represent not only substantial growth but equally risk..

IBC’s 2nd Annual Biosimilars Asia 2011 Summit is the ONLY conference in Asia catering to this region’s specific queries. With unprecedented insights from leading innovators and biosimilar companies, you will network and learn how to strategically position your company to maximize your ROI. Biosimilars Asia 2011 is attended by key stakeholders in the region and beyond, enabling you to make informed strategic decisions.

5 Reasons To Attend
  • Only conference in Asia which addresses concerns faced by the Asian biosimilar companies with experts from the region and beyond
  • Learn from and personally meet senior executives from the major stakeholders amongst from biosimilar to innovator companies
  • The most comprehensive event highlighting key challenges in the industry including manufacturing, marketing, pricing, transitioning from generics to biosimilars and regulatory issues
  • Showcasing unique case studies from leading Asian and international biosimilar companies
  • Gather the latest insights from regional biosimilar companies and MNCs about their strategic decisions and how they are positioning themselves for success

Industry Gurus / Speakers
Biocon, Pfizer, Genentech, Roche, Teva, Hospira, Sandoz, Momenta, Intas, Dr Reddy’s, Shenzhen Main Luck Pharmaceuticals

Past Attendees Include
Vice President, ASTRAZENECA INNOVATION CENTER (China)
Senior Director, GENENTECH INC, (USA)
Managing Director, BECTON DICKINSON CO (BD BIOSCIENCES) (Singapore)
Managing Director, ASAHI GLASS CO LTD (Japan)
Deputy General Manager, SINOPHARM (China)
Head, Biotech Research, USV LTD (India)
General Manager, JCR PHARMACEUTICALS CO LTD (Japan)
Vice President, R&D/Business Development, MAIN LUCK PHARMACEUTICALS INC (China)
Senior Research Associate, HANWHA CHEMICAL (South Korea)
Vice President, BOEHRINGER INGELHEIM GMBH (Germany)
General Manager, GLAXOSMITHKLINE (CHINA) INVESTMENT CO LTD (China)
IP Director, HOSPIRA (AUSTRALIA)
President, MYCENAX BIOTECH INC (Taiwan)
Senior Director, MERCK & CO INC (USA)
Associate Director, DR REDDY''''''''S LABORATORIES LTD (India)
Chairman, SHENZHEN SCIPROGEN BIO-PHARMACEUTICAL CO LTD (SCIPROGEN) (China)COO, SHANGHAI CELGEN BIOPHARMACEUTICALS (China)
Chief Representative, TTY BIOPHARM CO LTD (Taiwan)COO, 3SBIO (China)
Project Director, JIANGSU CHIA TAI TIANQING PHARMACEUTICAL CO LTD (China)Associate Director, PFIZER INVESTMENT CO LTD (China)
General Manager, NIPPON KAYAKU CO LTD (Japan)
President, HENLIUS BIOPHARMACEUTICALS INC & SHANGHAI HENLIUS BIOTECH (USA)
Vice President, RANBAXY (USA)

Registration

FEES per delegate
Early Bird Rate
Register & Pay before 11 March 2011
Special Rate
Register & Pay before 15 April 2011
Normal Rate
Register & Pay after 15 April 2011
Group Rate
Group of 3 or more
?
US$ / CNY
US$ / CNY
US$ / CNY
US$ / CNY
4 day package
(Conf + Pre & Post Workshops)
2,495 /
16,600
2,695 /
17,950
2,895 /
19,500
2,175 /
14,650
3.5 day package (Conf + Workshop C & A or B )

2,295 /
15,500

2,495 /
16,600
2,695 /
17,950
2,025 /
13,500
3 day package (Conf + Workshop A & B or C)
1,995 /
13,500
2,195 /
14,600
2,395 /
15,950

1,795 /
12,000

2.5 day package (Conf + Workshop A or B)
1,795 /
12,000
1,995 /
13,500
2,195 /
14,600
1,695 /
10,950
2 day package
(Conf only)
1,495 /
9,950
1,695 /
11,300
1,895 /
12,600
1,495 /
9,950

Register Now

PAYMENT TERMS

Payment must be received 10 business days prior to the event. To take advantage of discounts with an expiry cut-off date, registration and payment must be received by the cut off date.

Payments by Singapore Dollars (S$)

  • Payments by S$ bank draft or cheque should be made in favour of “IBC Asia (S) Pte Ltd” payable in Singapore.
  • Payment by telegraphic transfer in S$ must be made to:
    IBC Asia (S) Pte Ltd
    A/C No.: 147-059513-001 (SGD)
    The Hongkong and Shanghai Banking Corporation Limited
    21 Collyer Quay, HSBC Building, Singapore 049320
    Bank Swift Code: HSBCSGSG
    Bank Code: 7232
  • Payment by Credit Card (AMEX, VISA or MASTERCARD). Please provide your Card Number, Name of Cardholder, Expiry Date and your Signature and send it by fax to +65 6508 2407.
Payments by RMB (CNY)
  • Payment by telegraphic transfer in CNY must be made to:
    A/C Name:
    A/C No.: 720-031103-001
    Beneficiary Bank:
    Bank Address: No. 1000 Lujiazui Rind Road,
    Pudong, Shanghai 200120, P.R. China
    Bank Swift Code: HSBCCNSH
CANCELLATIONS SUBSTITUTION
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made available for cancellation notifications received less than 10 business days before the event.IMPORTANT NOTE:
Please quote the name of the delegate, event title and invoice number on the advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts. Please fax your payment details (copy of remittance advice, cheque or draft to +65 6508 2407.

Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.


DATA PROTECTION
The personal information entered during your registration/order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact Winnie Seah (Database) on winnie.seah@ibcasia.com.sg Tel: +65 6508 2468 or Fax: +65 6508 2408.
联系方式电话:+65 650 82401

2014.01.02 药监大考:制药企业迎来淘汰赛与淘金赛

12月31日,已有870家提出新修订药品GMP认证申请,其中855家已完成现场检查,通过检查并公告的企业有796家,占全部企业数量的60.3...GMP的认证。就药监局公布的数据显示,855家已完成现场检查,最后通过检查并公告的只有796家,其中还包括多次检查最后通过的部分,还有59家暂时没有通过
卒中后抗血小板出血风险有多大?有这10个特征需谨慎

2017.08.13 卒中后抗血小板出血风险有多大?有这10个特征需谨慎

)(即 S2TOP-BLEED 评分模型,见表1)。表 1 预测严重出血的S2TOP-BLEED 评分(来自多变量 Cox 回归模型)具体评分方法为,根据患者临床特征评估 S2TOP-BLEED 评分列表中每一栏分值,除了年龄相关的项目外,将其他所有项目分值想加得总分,再将总分代入图 1 所示风险分布图中,得到不同
远程协作治疗创伤后应激障碍

2014.12.23 远程协作治疗创伤后应激障碍

明,使用远程医疗工具,如电话,互动视频和共享电子病历进行的多学科PTSD非现场干预,即创伤后应激障碍远程医疗服务(TOP)与常规护理(UC)相比,治疗效果显著提升...包括了2009年11月至2011年9月份在CBOCs接受治疗的265名主要生活在农村的退伍军人。所有患者均符合PTSD诊断标准,他们被随机分配接受TOP治疗(N
说好的 PLUS 会员来啦!说明书上传 3 月排行榜出炉

2022.04.06 说好的 PLUS 会员来啦!说明书上传 3 月排行榜出炉

到了 825 份说明书,经过后台小助手日以继夜的审核,最终角逐出「3 月说明书上传榜」前三名:Top 1: 楠楠一沐 有效说明书 43 份Top 2: Eric_xzt 有效说明书 20 份Top 3: dxy_00wxf3se
中国的科研用户都在搜什么文献?

2016.04.25 中国的科研用户都在搜什么文献?

这点是无疑的,肿瘤研究是并且也将一直是科研用户最关注的点,那么紧接着就让我们看看中国的科研用户更关注哪些疾病的研究?最关注的疾病类型 TOP10从以上排名来看... (分别为:糖尿病和 HIV),从某一个角度上说明了这两种疾病所受的关注度与肿瘤疾病不相上下。接着从用户检索的关键词中统计出了中国科研用户最关注的基因 TOP
2014年FDA批准新药的销售额预测

2014.07.08 2014年FDA批准新药的销售额预测

重磅炸弹。按照Bloomberg的预测,2013年上市的新药经过5年的市场推广和培育,销售额top10的新药都将迈过10亿美元的门槛,2018年这10个新药的销售额...药物Xtandi同样备受关注,但 5年之后(即2017年)top10的销售总额预计仅为大约150亿美元,可以说完败于2013年。进入2014年, FDA在1~6

2012.05.02 风向变了,Good Bye, SCI

, SCI”还不是一个很容易的事情。无论如何,这仅仅是时间的问题,早晚的事情。数年前(2008年初),大呆曾经写过一个系列的博文《Top Journals 是标准吗》,对SCI这个问题有过比较系统的阐述,现在看来,当时的一些观点并没有过时。特别是,在Top Journals 是标准吗-7和Top

2011.08.15 三维CT重建的计算机模拟技术在伯尔尼髋臼周围截骨术中的应用

龄为14-42岁,平均24岁。术前行髋关节螺旋CT扫描并进行三维重建,使用“Top View”技术及Azuma分级对股骨头覆盖程度进行评估...^o(-10^o-18^o),Top View的股骨头覆盖率平均为63.5%(50%-77%)。术后平均外侧CE角为30.1^o(13^o-47^o),臼顶倾斜角
上一页 1 2 3 ... 20 21 22 ... 48 49 50 下一页 到第